磷酸西格列汀治疗新诊断2型糖尿病的临床观察

目的 观察用磷酸西格列汀治疗新诊断T2DM的有效性和安全性. 方法 139例新诊断T2DM患者,按照HbA1 c水平分为A、B、C3组,采用二肽基肽酶-4（DPP-4）抑制剂磷酸西格列汀100 mg,1次/d口服治疗,持续治疗52周. 结果 治疗52周后,3组HbA1c分别由12.0％、8.4％、6.8％降至7.1％、6.9％、6.5％.FBG、2hBG、胰岛素释放水平与治疗前比较差异均有统计学意义（P＜0.05）.肝肾功能、血脂、UAlb、BMI与治疗前比较差异无统计学意义（P＞0.05）.有3例发生低血糖事件,未发生其他不良反应. 结论 用磷酸西格列汀治疗新诊断T2DM患者,可安全有效地降低HbA1c及7个时点（三餐前后、睡前）血糖.

Clinical observation of sitagliptin phosphate treatment of newly diagnosed type 2 diabetes

Objective To observe the efficiency and safety of sitagliptin phosphate treatment in newly diagnosed type 2 diabetes. Methods A total of 139 patients with newly diagnosed type 2 diabetes were divided into A, B and C groups. In accordance with the level of glycated hemoglobin. 52-weeks of treatment was used, with 100 mg of dipeptidyl peptidase 4 （DPP-4） inhibitorsitagliptin phosphate once a day. Results After 52 weeks, HbA1 c were decreased from 12. 0~, 8. 4%, 6. 8~ to 7. 1~, 6. 9%, 6.5~ in A, B, C groups respectively. FBG, 2 hBG and insulin release level had statistically significant differences compared with those before treatment （P〈0.05）. The levels of liver and kidney function, blood lipid, urinary albumin, body mass index had no significant difference among three groups compared with those before treatment （P〈0.05）. Three cases had hypoglycemia reaction symptoms, and other adverse reactions were not found. Conclusion Using sitagliptin phosphaic to treat newly dignosed type 2 diabetes can reduce glycosylated hemoglobin and 7 time points of blood glucose （before and after meals, at bedtime） safely, effectively, conveniently and reliably.